SCHEMBL3756971

SCHEMBL3756971

CCCCNC(=O)C1c2ccccc2C(=O)N1C(c1ccccc1)c1ccccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 7/20 0.51
KCNH2 Q12809 3/20 0.51
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
SCN9A Q15858 3/20 0.42
SCN5A Q14524 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
ALDH1A1 P00352 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTT P42858 2/20 0.39
ASAH1 Q13510 1/20 0.39
GAA P10253 1/20 0.39
BRS3 P32247 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3755711 0.89 KCNA5 (0.58) KCNA5KCNH2SMN1; SMN2TSHRKMT2A
SCHEMBL3757498 0.85 KCNA5 (0.66) KCNA5KCNH2CYP2C19SCN9ASCN5A
SCHEMBL3754031 0.83 KCNA5 (0.60) KCNA5KCNH2SCN9ASMN1; SMN2TSHR
SCHEMBL3751907 0.81 KCNA5 (0.58) KCNA5KCNH2SCN9ASCN5A
SCHEMBL3750582 0.80 KCNA5 (0.64) KCNA5KCNH2SMN1; SMN2TSHRKMT2A
SCHEMBL3757738 0.79 KCNA5 (0.60) KCNA5KCNH2KDM4EPOLBCYP2C19
SCHEMBL3752544 0.78 KCNA5 (0.63) KCNA5KCNH2SCN9ASCN5ATSHR
SCHEMBL3752614 0.77 KCNA5 (0.56) KCNA5KCNH2SCN9ASCN5ATSHR
SCHEMBL4204175 0.77 KCNA5 (0.56) KCNA5KCNH2SCN9ASCN5ATSHR
SCHEMBL3755150 0.76 KCNA5 (0.53) KCNA5KCNH2SCN9ASCN5ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 KCNA5 69/4885KCNH2 2/4885KDM4E 4057/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 KCNA5 72/4885KCNH2 2/4885KDM4E 4100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.